Haldipurkar Tanvi Suhas, Haldipurkar Suhas, Venkatramani Devendra, Walavalkar Ruta, Deshpande Sarita, Setia Maninder Singh
Laxmi Eye Institute and Laxmi Charitable Trust, Panvel, India.
Clin Ophthalmol. 2024 Oct 16;18:2929-2937. doi: 10.2147/OPTH.S484030. eCollection 2024.
To assess the visual outcomes in patients bilaterally implanted with novel Clareon intraocular lens when targeting mini monovision post-operatively.
The study was conducted at Laxmi Eye Institute; it is a tertiary care eye institution in Panvel, India.
This is an investigator initiated, prospective, single-centre longitudinal study of 45 patients to assess the visual outcomes in patients who were implanted with Clareon IOL bilaterally.
Patients with corneal astigmatism of ≤0.75 D who underwent bilateral cataract surgery with pseudophakic mini-monovision and implanted with novel Clareon intraocular lens were included. Patients having post op manifest refraction >±0.25 D in the dominant eye and <-0.5 D or >-0.75 D in the non-dominant eye were excluded. The main study outcomes were assessed at 1 and 3 months; it included uncorrected visual acuities assessment, defocus curve, and patient reported spectacle use.
The mean (SD) binocular distance corrected intermediate visual acuity at 3 months was 0.22 (0.09) LogMAR. At 3 months, 54% of patients enjoyed 0.4 LogMAR or better BUCNVA. The defocus curve showed good distance and intermediate visual acuity with >0.2 LogMAR vision from +0.50 D to -1.50 D. We found a positive correlation between the Q value of the dominant eye and the BCIVA at 3 months postoperatively, however it was not statistically significant. The Q value was more negative when the intermediate vision was closer to 0 LogMAR. Post operatively, at 3 months, 95% patients did not need glasses for distance and intermediate vision and 73% of patients were comfortable for intermediate vision without glasses all the time.
Mini-monovision with Clareon monofocal IOL implantation can offer overall satisfactory vision for far and intermediate distances with minimal need for use of spectacles for near vision.
评估双侧植入新型Clareon人工晶状体并术后目标为微单眼视的患者的视觉效果。
该研究在拉克希米眼科研究所进行;它是印度潘维尔的一家三级眼科护理机构。
这是一项由研究者发起的、针对45例患者的前瞻性、单中心纵向研究,旨在评估双侧植入Clareon人工晶状体的患者的视觉效果。
纳入角膜散光≤0.75 D、接受双侧白内障手术并植入人工晶状体微单眼视且植入新型Clareon人工晶状体的患者。排除术后主眼明显屈光不正>±0.25 D且非主眼<-0.5 D或>-0.75 D的患者。主要研究结果在1个月和3个月时进行评估;包括未矫正视力评估、散焦曲线以及患者报告的眼镜使用情况。
3个月时双眼距离矫正后中间视力的平均值(标准差)为0.22(0.09)LogMAR。3个月时,54%的患者双眼未矫正近视力达到0.4 LogMAR或更好。散焦曲线显示在+0.50 D至-1.50 D范围内,远视力和中间视力良好,视力>0.2 LogMAR。我们发现主眼的Q值与术后3个月的最佳矫正视力之间存在正相关,但无统计学意义。当中间视力更接近0 LogMAR时,Q值更负。术后3个月,95%的患者在看远和中间距离时不需要眼镜,73%的患者在看中间距离时一直不戴眼镜也感觉舒适。
植入Clareon单焦点人工晶状体的微单眼视可为远和中间距离提供总体令人满意的视力,看近时对眼镜的需求最小。